Abstract
Purpose
The aim of this study was to evaluate the therapeutic efficacy of tolvaptan, a vasopressin V2 receptor antagonist, on edema in two rat models: 1) histamine-induced vascular hyperpermeability of the dorsal skin and 2) carrageenan-induced paw edema.
Methods
In the skin vascular hyperpermeability model, 3 h after oral administration of tolvaptan or the natriuretic agent furosemide, rats were intravenously injected with Evans Blue (EB), followed by intradermal injection of 10 μg of histamine into the dorsal skin. One hour later, blood was collected to measure serum parameters. EB leakage area into the dorsal skin was also measured. Urine was collected for 4 h to determine urine parameters. In the paw edema model, edema was induced by injecting 1% w/v carrageenan into the right hind paw. Paw volume was measured hourly for 5 h. Tolvaptan or furosemide was orally administered 1 h before carrageenan injection.
Results
A single oral dose of tolvaptan (1–10 mg/kg) elicited marked and dose-dependent aquaresis, and improvements in edema. Similar effects were observed with furosemide (30 mg/kg). Tolvaptan tended to elevate the serum sodium level while furosemide caused a significant decrease.
Conclusion
Tolvaptan had anti-edematous effects in two different rat models. By increasing free water excretion, tolvaptan may be more advantageous for certain patients than loop diuretics because it does not cause electrolyte loss, and may prevent electrolyte abnormities, such as hyponatremia. These results suggest that tolvaptan has potential clinical benefits for the treatment of edema.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Morrison JP. Edema and principles of diuretic use. Med Clin N Am. 1997;81:689–704.
Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273–8.
Palmer BF. Potassium disturbances associated with the use of diuretics. In: Seldin D, Giebisch G, editors. Diuretic agents—clinical physiology and pharmacology. San Diego: Academic; 1997. p. 571–83.
Rivera-Santos A, Star R. Sodium: Volume depletion and hyponatremia. In: Seldin D, Giebisch G, editors. Diuretic agents—clinical physiology and pharmacology. San Diego: Academic Pressl; 1997. p. 559–69.
Morel A, O’Carrol A, Brownstein MJ, Lolait SJ. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature. 1992;356:523–6.
Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem. 1994;269:3304–10.
De Keyzer Y, Auzan C, Lenne F, et al. Cloning and characterization of human V3 pituitary vasopressin receptor. FEBS Lett. 1994;356:215–20.
Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S, Kawashima H. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem. 1994;269:27088–92.
Birnbaumer M, Seibold A, Gilbert S, et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature. 1992;357:333–5.
Lolait SJ, O’Carroll AM, McBride OW, Konig M, Morel A, Brownstein MJ. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature. 1992;357:336–9.
Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol. 2002;29:1–9.
Kondo K, Ogawa H, Yamashita H, et al. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-metylbenzoyl-amino) benzoyl] -2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg Med Chem. 1999;7:1743–54.
Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860–7.
Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288–94.
Inoue S, Kido H, Hayashi K, Kubo Y, Uchida T, Watanabe M. Effects of a novel loop diuretic, torasemide, on several kinds of edematous models of rats. KISO TO RINSHO. 1996;30:489–96.
Veeraveedu PT, Watanabe K, Ma M, et al. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol. 2008;75:1322–30.
Tsuboi Y, Ishikawa S, Fujisawa G, Okada K, Saito T. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int. 1994;46:237–44.
Fernández-Varo G, Ros J, Cejudo-Martín P, et al. Effect of the V1a/V2-AVP receptor antagonist, conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol. 2003;38:755–61.
Jiménez W, Gal CS, Ros J, et al. Long-term aquaretic efficacy of a selective nonpeptide V2-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J Pharmacol Exp Ther. 2000;295:83–90.
Ros J, Fernández-Varo G, Muñoz-Luque J, et al. Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention. Br J Pharmacol. 2005;146:654–61.
Okada T, Sakaguchi T, Hatamura I, et al. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. Clin Exp Nephrol. 2009;13:438–46.
Chabardes D, Gagman-Brunette M, Imbert-Teboul M, et al. Adenylate cyclase responsiveness to hormones in various portions of the human nephron. J Clin Invest. 1980;65:439–48.
Chabardes D, Imbert-Teboul M, Gagnan-Brunette M, Morel F. Difference hormone target sites along the mouse and rabbit nephrons. Curr Probl Clin Biochem. 1977;8:447–54.
Hall DA, Varney DM. Effect of vasopressin electrical potential difference and chloride transport in mouse medullary thick ascending limb of Henle’s loop. J Clin Invest. 1980;66:792–802.
Morel F. Sites of hormone action in the mammalian nephron. Am J Physiol. 1981;240:F159–64.
Ruggles BT, Murayama N, Werness JL, Gapstur SM, Bentley MD, Dousa TP. The vasopressin-sensitive adenylate cyclase in collecting tubules and in the thick ascending limbs of Henle’s loop of human and canine kidney. J Clin Endocrinol Metab. 1985;60:914–21.
Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–71.
Konstam MA, Gheorghiade M, Burnett Jr JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319–31.
Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332–43.
De Bruyne LKM. Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J. 2003;79:268–71.
Acknowledgments
The authors express their thanks to Dr Yongee Liu for critically reviewing this manuscript. The authors also thank Dr Masafumi Shibamori and Mr Takahiro Asakuni for their excellent technical assistance.
Disclosures
None of the authors have any conflicts of interest associated with this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miyazaki, T., Sakamoto, Y., Yamashita, T. et al. Anti-edematous Effects of Tolvaptan in Experimental Rodent Models. Cardiovasc Drugs Ther 25 (Suppl 1), 77–82 (2011). https://doi.org/10.1007/s10557-011-6355-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-011-6355-z